Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer

被引:293
作者
Pyka, Thomas [1 ]
Okamoto, Shozo [1 ,2 ]
Dahlbender, Marielena [3 ]
Tauber, Robert [3 ]
Retz, Margitta [3 ]
Heck, Matthias [3 ]
Tamaki, Nagara [2 ]
Schwaiger, Markus [1 ]
Maurer, Tobias [3 ]
Eiber, Matthias [1 ]
机构
[1] Tech Univ Munich, Klinikum Rechts Isar, Dept Nucl Med, Ismaninger Str 22, D-81675 Munich, Germany
[2] Hokkaido Univ, Dept Nucl Med, Grad Sch Med, Sapporo, Hokkaido, Japan
[3] Tech Univ Munich, Klinikum Rechts Isar, Dept Urol, Munich, Germany
关键词
68Ga-PSMA; Bone scintigraphy; Prostate cancer; Bone metastasis; SPECT; METASTASIS; INHIBITOR; DIAGNOSIS; SCAN;
D O I
10.1007/s00259-016-3435-0
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The aim of our study was to compare the diagnostic performance of Ga-68-PSMA PET and Tc-99m bone scintigraphy (BS) for the detection of bone metastases in prostate cancer (PC) patients. One hundred twenty-six patients who received planar BS and PSMA PET within three months and without change of therapy were extracted from our database. Bone lesions were categorized into benign, metastatic, or equivocal by two experienced observers. A best valuable comparator (BVC) was defined based on BS, PET, additional imaging, and follow-up data. The cohort was further divided into clinical subgroups (primary staging, biochemical recurrence, and metastatic castration-resistant prostate cancer [mCRPC]). Additionally, subgroups of patients with less than 30 days delay between the two imaging procedures and with additional single-photon emission computed tomography (SPECT) were analyzed. A total of 75 of 126 patients were diagnosed with bone metastases. Sensitivities and specificities regarding overall bone involvement were 98.7-100 % and 88.2-100 % for PET, and 86.7-89.3 % and 60.8-96.1 % (p < 0.001) for BS, with ranges representing results for 'optimistic' or 'pessimistic' classification of equivocal lesions. Out of 1115 examined bone regions, 410 showed metastases. Region-based analysis revealed a sensitivity and specificity of 98.8-99.0 % and 98.9-100 % for PET, and 82.4-86.6 % and 91.6-97.9 % (p < 0.001) for BS, respectively. PSMA PET also performed better in all subgroups, except patient-based analysis in mCRPC. Ga-PSMA PET outperforms planar BS for the detection of affected bone regions as well as determination of overall bone involvement in PC patients. Our results indicate that BS in patients who have received PSMA PET for staging only rarely offers additional information; however, prospective studies, including a standardized integrated x-ray computed tomography (SPECT/CT) protocol, should be performed in order to confirm the presented results.
引用
收藏
页码:2114 / 2121
页数:8
相关论文
共 23 条
[1]   The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer [J].
Afshar-Oromieh, Ali ;
Avtzi, Eleni ;
Giesel, Frederik L. ;
Holland-Letz, Tim ;
Linhart, Heinz G. ;
Eder, Matthias ;
Eisenhut, Michael ;
Boxler, Silvan ;
Hadaschik, Boris A. ;
Kratochwil, Clemens ;
Weichert, Wilko ;
Kopka, Klaus ;
Debus, Juergen ;
Haberkorn, Uwe .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (02) :197-209
[2]  
[Anonymous], J NUCL MED MOL IMAGI
[3]   Metastatic patterns of prostate cancer:: An autopsy study of 1,589 patients [J].
Bubendorf, L ;
Schöpfer, A ;
Wagner, U ;
Sauter, G ;
Moch, H ;
Willi, N ;
Gasser, TC ;
Mihatsch, MJ .
HUMAN PATHOLOGY, 2000, 31 (05) :578-583
[4]   68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging [J].
Eder, Matthias ;
Schaefer, Martin ;
Bauder-Wuest, Ulrike ;
Hull, William-Edmund ;
Waengler, Carmen ;
Mier, Walter ;
Haberkorn, Uwe ;
Eisenhut, Michael .
BIOCONJUGATE CHEMISTRY, 2012, 23 (04) :688-697
[5]   Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy [J].
Eiber, Matthias ;
Maurer, Tobias ;
Souvatzoglou, Michael ;
Beer, Ambros J. ;
Ruffani, Alexander ;
Haller, Bernhard ;
Graner, Frank-Philipp ;
Kuebler, Hubert ;
Haberhorn, Uwe ;
Eisenhut, Michael ;
Wester, Hans-Juergen ;
Gschwend, Juergen E. ;
Schwaiger, Markus .
JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (05) :668-674
[6]  
Even-Sapir E, 2006, J NUCL MED, V47, P287
[7]  
Even-Sapir E, 2005, J NUCL MED, V46, P1356
[8]   EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent-Update 2013 [J].
Heidenreich, Axel ;
Bastian, Patrick J. ;
Bellmunt, Joaquim ;
Bolla, Michel ;
Joniau, Steven ;
van der Kwast, Theodor ;
Mason, Malcolm ;
Matveev, Vsevolod ;
Wiegel, Thomas ;
Zattoni, F. ;
Mottet, Nicolas .
EUROPEAN UROLOGY, 2014, 65 (01) :124-137
[9]   Bone scanning in clinical oncology: does it have a future? [J].
Jacobson, AF ;
Fogelman, I .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1998, 25 (09) :1219-1223
[10]   Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial [J].
Jambor, Ivan ;
Kuisma, Anna ;
Ramadan, Susan ;
Huovinen, Riikka ;
Sandell, Minna ;
Kajander, Sami ;
Kemppainen, Jukka ;
Kauppila, Esa ;
Auren, Joakim ;
Merisaari, Harri ;
Saunavaara, Jani ;
Noponen, Tommi ;
Minn, Heikki ;
Aronen, Hannu J. ;
Seppanen, Marko .
ACTA ONCOLOGICA, 2016, 55 (01) :59-67